CSI Market
Sign In | Register

Lisata Therapeutics Inc (LSTA) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access LSTA Annual Cash Flow →
Tracking cash flow results across Lisata Therapeutics Inc to Jun 30 2025 helps illustrate how Jun 30 2026's cash generation has responded to changing business conditions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-7.42
Depreciation & amortization0.01
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation0.58
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), Unrealized0.00
Provision For Reduction Of Doubtful Accounts-
Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities0.23
Impairment Of Intangible Assets Excluding Goodwill-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Accounts Payable0.00
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-1.20
Other Working Capital-0.02
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities2.33
Discontinued operations0.00
Net Cash flow from Operating Activities-5.73
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities0.00
Payments to Acquire Marketable Securities0.00
Real Estate Investments0.00
Payments For Merger Related Costs Investing Activities-
Payments For Asset Acquisition Costs Net-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.01
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.37
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net-0.16
Other net0.00
Proceeds From Stock Option And Warrant Excercises-
Payment For Warrant Inducement-
Cash and Cash Equivalents at Carrying Value Including Discontinued Operations Beginning Balance-
Cash and Cash Equivalents Ending Balance-
Change In Warrant Liabilities-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.21
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-5.73
Total Cash Flow-5.51
4 historic quarters locked

Sign in to unlock the full Lisata Therapeutics Inc cash flow history.

Sign In Create Free Account

About Lisata Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000320017-26-000038

Figures are derived from filed reports and may be restated. Historical data is subject to revision.